Jamjoom Pharmaceuticals Factory Co

SAU:4015Healthcaretasi

——At close · Market cap — · Next earnings Tue 27 Oct

SAR billions	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	TTM	YoY
Revenue	0.8	0.7	0.9	1.1	1.3	1.5	1.6	+4.9%
Cost of revenue	0.3	0.3	0.3	0.4	0.5	0.6	0.6	+3.7%
Gross profit	0.5	0.5	0.6	0.7	0.8	0.9	1.0	+5.5%
Research & development	0.0	0.0	0.0	0.0	0.0	0.0	0.0	+12.5%
Selling, general & administrative	0.1	0.1	0.2	0.2	0.2	0.2	—	—
Selling & marketing	0.1	0.1	0.2	0.2	0.2	0.2	—	—
Operating expenses	0.3	0.3	0.4	0.4	0.4	0.5	0.5	+8.8%
Operating income	0.2	0.2	0.2	0.3	0.4	0.5	0.5	+6.3%
Interest expense	0.0	0.0	0.0	0.0	0.0	0.0	0.0	+1523.8%
Interest income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	—
Other income / expense	(0.0)	0.0	(0.0)	0.0	0.0	0.0	—	—
Pre-tax income	0.2	0.2	0.2	0.3	0.4	0.5	0.5	+2.3%
Income tax	0.0	0.0	0.0	0.0	0.0	0.0	0.0	+5.2%
Net income	0.2	0.2	0.2	0.3	0.4	0.5	0.5	+3.6%
Discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	—	—
Other net income adjustments	(0.0)	(0.0)	(0.0)	0.0	0.0	0.0	—	—
EPS, basic (per share)	2.96	2.44	2.45	4.18	5.10	6.60	6.86	+4.0%
EPS, diluted (per share)	2.96	2.44	2.45	4.18	5.10	6.60	6.86	+4.0%
EBITDA	0.3	0.2	0.2	0.3	0.4	0.5	0.5	+6.7%
Depreciation & amortization	0.0	0.0	0.0	0.0	0.0	0.0	0.0	+10.7%
Weighted average shares (shares)	70,000,000	70,000,000	70,000,000	70,000,000	70,000,000	70,273,000	—	—
Weighted average diluted shares (shares)	70,000,000	70,000,000	70,000,000	70,000,000	70,000,000	70,273,000	—	—
Gross margin	63.7%	64.5%	64.8%	63.7%	62.2%	62.6%	63.0%	+0.4 pts
Operating margin	30.8%	25.4%	25.5%	28.5%	28.9%	30.7%	31.1%	+0.4 pts
Net margin	25.7%	23.2%	18.7%	26.6%	27.0%	30.9%	30.5%	−0.4 pts

SAR billionsUpdated Wed 22 Jul ·

ⓘ

Amounts are shown in the stated units; per-share amounts and shares are unscaled. Negative amounts are in brackets.

TTM ends 2026-06-30 and uses four consecutive reported quarters.